Copyright
©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Meta-Anal. Nov 26, 2013; 1(3): 121-129
Published online Nov 26, 2013. doi: 10.13105/wjma.v1.i3.121
Published online Nov 26, 2013. doi: 10.13105/wjma.v1.i3.121
Meta-analysis of anti-ribosomal P antibodies in lupus psychosis
Kim Linz, Brian J Miller, Department of Psychiatry and Health Behavior, Georgia Regents University, Augusta, GA 30912, United States
Author contributions: Miller BJ designed the research; Linz K and Miller BJ managed the literature searches; Miller BJ managed the analyses; Linz K and Miller BJ wrote the first draft of the manuscript, and have approved the final manuscript.
Supported by The National Institute of Mental Health (1K23MH098014) and Georgia Regents University; and honoraria from Medscape, Insight Consulting, and Decision Resources Group
Correspondence to: Brian J Miller, MD, PhD, MPH, Department of Psychiatry and Health Behavior, Georgia Regents University, 997 Saint Sebastian Way, Augusta, GA 30912, United States. brmiller@gru.edu
Telephone: +1-706-7214445 Fax:+1-706-7216602
Received: May 24, 2013
Revised: October 16, 2013
Accepted: October 19, 2013
Published online: November 26, 2013
Revised: October 16, 2013
Accepted: October 19, 2013
Published online: November 26, 2013
Core Tip
Core tip: In a meta-analysis of twenty-four studies, positive anti-ribosomal P (aRP) antibodies were found in 51% (91 of 179 total cases) of cases of lupus psychosis. There was an almost 3.5-fold increased odds of psychosis in aRP-positive patients (OR = 3.46, 95%CI: 1.97-6.09, P < 0.001). The population attributable risk percentage was 36% for aRP antibodies. aRP antibodies are common in lupus psychosis, although the potential mechanism(s) underlying this association remain unclear. Given the overlap between the clinical presentation and risk factors for lupus psychosis and schizophrenia, further investigation of aRP antibodies in schizophrenia is warranted.